|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Supplemental Material 2. Sensitivity analysis for baseline phases for sleep duration assessment | | | | | | | | | |
| Sleep duration | Baseline phase | Person-years | N | All-cause death1 | | Cancer death2 | | CVD death3 | |
| Number  of deaths | HR (95% CI) 4 | Number  of deaths | HR (95% CI) 4 | Number  of deaths | HR (95% CI) 4 |
| < 6 hours | Phase 1 | 55 325 | 5034 | 169 | 1.09 (0.92-1.29) | 80 | 1.01 (0.79-1.29) | 32 | 1.15 (0.77-1.70) |
| Phase 2 | 45 514 | 5591 | 152 | 1.21 (1.01-1.43) | 89 | 1.31 (1.15-1.43) | 15 | 0.70 (0.41-1.19) |
| *Heterogeneity (P)*5 | |  |  | 0.41 |  | 0.07 |  | 0.15 |
|  |  |  |  |  |  |  |  |  |  |
| 6 to < 8 hours | Phase 1 | 303 282 | 27 386 | 721 | 1.00 (ref) | 376 | 1.00 (ref) | 120 | 1.00 (ref) |
| Phase 2 | 383 122 | 47 466 | 861 | 1.00 (ref) | 434 | 1.00 (ref) | 134 | 1.00 (ref) |
|  |  |  |  |  |  |  |  |  |  |
| ≥8 hours | Phase 1 | 114 489 | 10 149 | 332 | 1.11 (0.98-1.27) | 165 | 1.08 (0.90-1.30) | 44 | 0.88 (0.62-1.24) |
| Phase 2 | 150 653 | 18 579 | 440 | 1.09 (0.97-1.22) | 219 | 1.11 (0.94-1.30) | 69 | 1.04 (0.78-1.39) |
| *Heterogeneity (P)*5 | |  |  | 0.84 |  | 0.83 |  | 0.47 |

HR, hazard ratio; CI, confidence interval; CVD, cardiovascular disease; ICD-10, the 10th revision of the International Classification of Disease

1 Cause of death identified by ICD-10 codes A00-Z99

2 Cause of death identified by ICD-10 codes C00-C97

3 Cause of death identified by ICD-10 codes I00-I99

4 HRs and 95% CIs results from Cox proportional hazards analysis, adjusted by age, sex, marital status, education level, BMI, smoking, drinking, physical activity, and comorbidity score

5 Heterogeneity of results of the two phases tested by Q-statistic